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ABSTRACT
Introduction: Recent data from the COMPARZ study seem to suggest a non-
inferiority of pazopanib confronted with sunitinib in PFS and OS. We previously 
reported how VEGF and VEGFR polymorphisms might have a predictive role in patients 
treated with first-line sunitinib. Aim of our study was to investigate whether tumour 
angiogenesis genotyping could influence clinical outcome in RCC patients treated with 
either sunitinib or pazopanib, in order to help clinicians select the appropriate 
treatment for each patient.
Results: 19 patients were treated with pazopanib while 78 received sunitinib. 
VEGF A rs833061 resulted significant in PFS in sunitinib vs pazopanib patients 
(CC+CT>TT in sunitinib, TT>CC+CT in pazopanib; p<0,0001); VEGF A rs2010963 
resulted significant in PFS in sunitinib vs pazopanib patients (GG+CG>CC in sunitinib, 
CC>GG+CG in pazopanib; p<0,0001); VEGF A rs699947 resulted significant in PFS in 
sunitinib vs pazopanib patients (AA+AC>CC in sunitinib, CC>AA+AC in pazopanib; 
p<0,0001). OS showed no statistically significant difference.
Conclusions: in our analysis patients with opposite polymorphisms of rs833061, 
rs2010963, rs699947 of VEGF A seems to have a better PFS if treated with either 
sunitinib or pazopanib. Our data seem to suggest that biology could have a role 
choosing first line treatment for mRCC patients.
Methods: a retrospective analysis on 97 histologic samples of mRCC patients 
was conducted for VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms 
(SNPs).
INTRODUCTION
Since the introduction of multitarget tyrosine-kinase 
inhibitors (TKIs) the survival scenario for metastatic 
renal cell carcinoma patients radically changed. Based 
on efficacy results, sunitinib was widely used as a first-
line treatment until 2010. The introduction of pazopanib, 
a novel multi target inhibitor, put on the market a new 
alternative first-line drug. These two drugs exploit their 
action through the inhibition of angiogenesis by molecular 
interaction with almost the same receptors (VEGFRs, 
PDGFR, and KIT) but with different affinity. Results from 
the COMPARZ study, the first phase III trial comparing 
sunitinib and pazopanib, has been recently published. This 
trial was designed to demonstrate a non-inferiority of these 
therapeutic options, in terms of efficacy and according to 
quality of life parameters. Although the study showed 
a non-inferiority in terms of PFS of pazopanib versus 
sunitinib, it also suggested that pazopanib might have a 
better tolerability [1]. On the one hand these two drugs can 
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be then considered valuable options for first-line treatment. 
However, on the other hand, a possible choice based on 
quality of life profiles may result questionable. In fact 
the questionnaires used, the timing of test administration 
and the possible influence between the patient and the 
physician are the major downsides of the analysis.
Globally, the possibility of a wider choice for first-
line treatment makes the research for predictive markers 
of response even more relevant to improve global clinical 
outcome. A more efficient selection would also allow 
avoiding unnecessary toxicities to potentially resistant 
patients.
Angiogenesis hyperactivation, as a compensatory 
response to hypoxia, is particularly important in RCC. 
RCC are, in fact, highly vascularized tumours and are 
frequently associated with mutations in VHL gene, a 
critical regulator of the hypoxic response, for the onset of 
the disease [2].
Single-nucleotide polymorphisms (SNPs) in the 
vascular endothelial growth factors (VEGF) and VEGF 
receptors (VEGFR) genes have been also correlated to 
tumour neoangiogenesis through different biological 
mechanisms.
Currently numerous evidence are contributing to 
correlate angiogenesis SNPs and global outcome in several 
diseases such as colorectal, breast and ovarian cancers, 
when treated with antiangiogenic therapy [3-7], but data 
in mRCC are lacking. In a study performed on blood 
samples and tumour tissue specimens, Kim et al. showed 
a statistically significant difference in patients with SNP 
-634 for sunitinib related hypertension [8]. Another study 
published by Garcia-Donas et al. correlated SNPs with 
response and toxicities in mRCC patients treated with 
sunitinib. Polymorphisms of VEGFR3 and CYP3A5*1 are 
proposed in this paper as potential markers of tolerability 
and response [9].
We previously reported how VEGF and VEGFRs 
SNPs are able to predict outcome in patients treated with 
sunitinib. VEGF A polymorphism rs833061, rs699947 and 
rs2010963 and VEGFR 3 rs6877011 seem to influence the 
outcome of patients with metastatic renal cell carcinoma 
treated with sunitinib [10].
Similarly the influence of various SNPs was 
assessed, in an unplanned analysis, by Xu et al. in patients 
enrolled in the pivotal trial about pazopanib. They 
evaluated in blood samples the correlation between SNPs 
of the angiogenic pathway, including some of VEGF, 
with survival and toxicity. In this study VEGFA _1498 
CC genotype compared with the TT genotype conferred 
inferior PFS and RR (33% v 51%) [11].
Recently Marisi et al. showed how polymorphisms 
expression of VEGF was preserved between peripheral 
blood and formalin fixed paraffin embedded tisues 
(FFPE) in patients with colorectal cancer. They analysed 
237 patients samples, peripheral blood was used for 153 
patients, whereas only FFPE tumor tissue was available 
for 84 patients. All VEGF and eNOS polymorphisms, 
apart from VEGF -1154G>A, were comparable in 
peripheral blood and FFPE samples, suggesting that FFPE 
tissue is a valuable source of biological material on which 
the majority of molecular studies can be performed. [12].
The aim of the present study is to assess whether 
a difference in polymorphisms expression could be able 
to predict different outcomes in patients treated with 
sunitinib or pazopanib.
RESULTS
The following SNPs met our selection criteria: 
VEGF-A: rs25648, rs10434, rs833061, rs699947, 
rs2010963, rs3025039; VEGF-C: rs4604006, rs7664413. 
VEGFR-1: rs664393, rs7993418; VEGFR-2: rs2071559, 
rs2305948, rs1870377, rs7667298; VEGFR-3: rs307822, 
rs307805, rs6877011 (Table 1).
All SNPs genotyped presented an overall call rate 
≥ 90%.
We have evaluated concentration and purity index 
of each sample by UV spectrophotometry as the ratio 
absorbance 260/280 nm. All samples presented a purity 
index between 1.5 and 2.0.
The frequencies of the tested genotypes resulted 
comparable to those reported in Caucasians, with no 
significant deviation from the Hardy-Weinberg equilibrium.
Linkage disequilibrium was observed for the tumour 
genotypes rs833061, rs699947 and rs2010963 of VEGF A 
(p>0,0001).
Ninety-seven patients with histologically proven 
mRCC, receiving first-line sunitinib or pazopanib were 
available for our analysis: 60 males and 18 females in the 
sunitinib group; 11 males and 8 females in the pazopanib 
group. Median age at diagnosis of 65 years (range 47-85) 
in the general population with 64 years for sunitinib and 
68 years for pazopanib (Table 2).
Seventy-five patients underwent renal surgery (77%, 
64 sunitinib, 15 pazopanib), for twenty-two patients 
only core biopsies were available (23%, 14 sunitinib, 
4 pazopanib). Thirty-six patients were metastatic at 
diagnosis (41%, 27 sunitinib, 9 pazopanib). Ninety 
patients had a clear cell renal cell carcinoma histology 
(74 sunitinib, 18 pazopanib), whether 7 patients presented 
undefined histology. All patients received sunitinib with 
standard schedule 50mg/die (4 weeks on/2 weeks off) or 
pazopanib at standard dose 800mg/die continuously as 
first-line treatment, dose reduction was applied in patients 
with grade 3 and 4 toxicities, as clinically indicated. 
Seventy-eight patients received sunitinib while 19 
received pazopanib.
In the general population median PFS was 6,79 
months, while median OS was 18,62 months.
No statistically significant differences were found 
according to treatment received for major patients 
characteristics (PS, tumour burden, grading, etc.).
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Survival analysis was conducted dividing patients 
according to the administered drug and for each drug 
according to the polymorphism expression.
Fifty-two patients (66%) expressed the CC+CT 
genotype of rs833061 while 26 (34%) expressed TT 
genotype in the sunitinib group, instead 13 (68%) CC+CT 
and 6 (32%) TT genotype in the pazopanib group. An 
advantage in median progression free survival was 
observed for patients expressing the CC+CT genotype in 
the sunitinib group (11,3 vs 4 months) and for patients 
with the TT genotype in the pazopanib group (9,3 vs 3,8 
months) (p<0,0001; logrank test: Chi-square 30,0448) 
(Figure 1).
Fifty-nine (76%) patients expressed the GG+CG 
genotype and 19 (24%) the CC genotype in the sunitinib 
group for rs2010963, while 15 (79%) showed GG+CG 
genotype and 4 (21%) CC genotype in the pazopanib 
treated group. Median PFS was improved for the GG+CG 
genotype in the sunitinib group (7,7 vs 1,9 months), in the 
pazopanib group the CC genotype correlated with a better 
PFS (13,18 vs 4,48 months) (p<0,0001; logrank test: Chi-
square 29,6518) (Figure 2).
Fifty-two patients (66%) showed the AA+AC 
genotype of rs699947 and CC genotype was expressed in 
26 (34%) patients treated with sunitinib; in the pazopanib 
group 13 (68%) showed the AA+AC and 6 (32%) the 
CC genotype. The AA+AC genotype demonstrated an 
improved median PFS for the sunitinib group (9,5 vs 
3,44) while CC genotype improved median PFS in the 
pazopanib group (9,1 vs 3,7 months) (p<0,0001; logrank 
test: Chi-square 35,6301) (Figure 3) (Table 3).
Overall survival analysis did not reach statistical 
significance possibly due to a shorter follow-up in the 
pazopanib group patients.
DISCUSSION
The principal molecular target for TKIs used in 
mRCC treatment is the VEGF pathway via inhibition 
of the tyrosine kinase activity of VEGF receptors-1, 2 
Table 1: Chromosomal locations, positions, biological effects and minor allele frequencies in the study population of 
investigated gene SNPs
SNP ID Gene Chr Chr. Position
Position in the 
gene/Effect
Codon 
exchange aa. exchange
Minor allele 
frequencies
rs10434 VEGFA 6 43753212 3'UTR(c) - - A - 40,43%
rs2010963 VEGFA 6 43738350 5'UTR(d) - - C - 32,29%
rs25648 VEGFA 6 43738977 Syn(a); ESE(b) TCC fi TCT S [Ser] fi S [Ser] T - 17,02%
rs3025039 VEGFA 6 43752536 3'UTR(c) - - T - 16,67%
rs699947 VEGFA 6 43736389 Prom(e) - - C - 50,00%
rs833061 VEGFA 6 43737486 Prom(e) - - T - 48,91%
rs4604006 VEGFC 4 177608775 Intronic - - T - 19,79%
rs7664413 VEGFC 4 177608707 Intronic - - T - 8,51%
rs664393 FLT1 13 29071001 3'UTR(c) - - A - 12,77%
rs7993418 FLT1 13 28883061 Syn(a); ESE(b) TAC fi TAT Y [Tyr] fi Y [Tyr] G - 22,92%
rs1870377 KDR 4 55972974 Missense CAA fi CAT Q [Gln] fi H [His] A - 18,18%
rs2071559 KDR 4 55992366 Init. Transcription - - T - 45,83%
rs2305948 KDR 4 55979558 Missense GTA fi ATA V [Val] fi I [Ile] T - 3,13%
rs7667298 KDR 4 55991731 5'UTR(d) - - T - 48,96%
rs307805 FLT4 5 180077487 Prom(e); TFBS(g) - - A - 7,45%
rs6877011 FLT4 5 180029471 3'UTR(c) - - G - 5,56%
rs307822 FLT4 5 180028717 3'UTR(c) - - G - 12,77%
(a) Syn: Synonymous substitution; (b) ESE: Exon Splicing Enhancer; (c) 3’UTR: Untranslated Region 3'UTR; (d) 5’UTR: 
Untranslated Region 5'UTR; (e) Prom: Promoter region; (g) TFBS: Predicted Trascription Factor Binding Site.
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and 3. However, TKIs are unspecific and inhibit a broad 
spectrum of other receptor tyrosine kinases to varying 
degrees. Newer TKIs have greater target selectivity and 
affinity for VEGF receptors and data suggest that these 
agents may cause fewer and/or less severe off-target, non-
VEGF related side effects [13, 14]. However, off-target 
side effects are still observed with the newer TKIs and, 
in the case of pazopanib, also novel toxicities such as an 
increased risk of hepatic toxicity are described [15].
The ability to inhibit the key targets such as 
VEGF receptors and PDGFR is proposed to account 
for the efficacy of TKIs. TKIs with high affinity for 
VEGF receptors might therefore be expected to be more 
effective than TKIs with a lower affinity. However, 
median progression-free survival (PFS) of approximately 
11 months is achieved with both the high affinity, more-
selective TKI pazopanib [16, 17] and the lower-affinity 
TKI sunitinib. Differences in trial design, patient numbers 
and the use of dose reduction (sunitinib drug exposure 
[area under the curve] correlates with efficacy: reduced 
doses lead to reduced overall efficacy) [18] may partially 
explain these observations. Another explanation supported 
by preclinical pharmacokinetic data suggests a critical 
threshold for VEGF and other receptor inhibition by 
TKIs beyond which no additional gain in overall clinical 
efficacy is achieved [19].
Combined analysis on our series according to 
the administered drug showed a better PFS for patients 
expressing CC+CT polymorphism of rs833061, GG+CG 
polymorphism of rs2010963, AA+AC polymorphism of 
rs699947 in sunitinib patients, while TT polymorphism 
of rs833061, CC polymorphism of rs2010963, CC 
polymorphism of rs699947 in pazopanib patients. 
rs833061 is located in the promoter region of the VEGF A 
gene on chromosome 6, as rs699947. Instead rs2010963 
is located in the terminal 5’ UTR region of the VEGF A 
Table 2: Patients’ characteristics
Sunitinib Pazopanib
Number of patients 78 19
Gender Male 60 (77%) 11 (58%)
Female 18 (33%) 8 (42%)
Median age (range 47-84) >65 38 (49%) 10 (53%)
<65 40 (51%) 9 (47%)
Surgery Yes 64 (82%) 15 (79%)
No 14 (18%) 4 (21%)
Histology Clear cell 73 (93%) 17 (89%)
Other 5 (7%) 2 (11%)
ECOG 0 57 (73%) 13 (68%)
1 13 (17%) 4 (21%)
2 8 (10%) 2 (11%)
Stage at diagnosis
(AJCC Cancer Staging Manual. 2010) I 4 (5%) 0 (0%)
II 7 (9%) 1 (5%)
III 40 (51%) 8 (42%)
IV 27 (35%) 9 (47%)
Best Response CR 1 (1%) 0 (0%)
PR 9 (12%) 2 (10%)
SD 23 (29%) 7 (37%)
PD 45 (58%) 10 (53%)
Risk classification (Heng score) Favourable 20 (26%) 5 (26%)
Intermediate 44 (56%) 11 (57%)
Poor 14 (18%) 3 (17%)
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Figure 1: Progression Free Survival analysis of rs833061 (p<0,0001). (------ CC+CT sunitinib) (••••• TT pazopanib) ( _____
TT sunitinib) (−•−•−•− CC+CT pazopanib). Different polimorphisms expression confers a significant difference in outcome (p<0,0001; 
logrank test: Chi-square 30,0448).
Figure 2: Progression Free Survival analysis of rs2010963 (p<0,0001). (------ CC sunitinib) (••••• GG+CG pazopanib) 
( _____CC pazopanib) (−•−•−•− GG+CG sunitinib). Different polimorphisms expression confers a significant difference in outcome 
(p<0,0001; logrank test: Chi-square 29,6518).
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Figure 3: Progression Free Survival analysis of rs699947 (p<0,0001). (------ AA+AC sunitinib) (••••• CC pazopanib) 
(______ AA+AC pazopanib) (−•−•−•− CC sunitinib). Different polimorphisms expression confers a significant difference in outcome 
(p<0,0001; logrank test: Chi-square 35,6301).
gene. We can hypothesize that different SNPs in different 
regions of the VEGF gene may influence circulating levels 
of VEGF and thus response to anti-VEGF therapies, but 
their exact extent of influence is still unknown.
These findings could explain how a certain 
constitutive variation in VEGF and VEGFR levels 
in tumour cells could exert a significant difference in 
outcome during antiangiogenic treatment, even though 
candidate gene studies exploring associations between 
VEGF polymorphisms and circulating VEGF levels have 
yielded controversial results. Eight studies have found 
significant associations with candidate polymorphisms 
(rs699947, rs1570360, rs833061, rs2010963, rs3025039, 
and 2549 18bp I/D) in the promoter, 5’, and 3’ untranslated 
regions of the VEGF gene [20-26]. However, several 
other studies did not identify any association with these 
and other VEGF SNPs. Using a hypothesis-free genome-
wide approach, Debette et al. found associations with 140 
SNPs. Of these, 68 SNPs are located on chromosome 6, 
approximately 150 kb downstream from the 3’ end of the 
VEGF gene, far from previously tested candidate SNPs 
[27]. However the real effect of SNPs in circulating or 
tumour tissues VEGF levels needs further studies in order 
to definitively associate a specific SNP to a specific effect 
on the corresponding growth factor or receptor.
Although we are unable to define the exact 
biological effect of a genotype on the protein expression, 
in our analysis we showed how a different pattern of 
expression of polymorphisms leads to a different outcome 
according to the first-line drug administered. To notice 
is the opposite expression of VEGF A polymorphisms in 
patients with better outcome with sunitinib or pazopanib. 
This finding is in accordance with our previous report 
on sunitinib patients and with the analysis conducted 
on patients enrolled in the pazopanib trial [10, 12]. On 
the contrary another study by Garcia-Donas didn’t 
find a correlation between PFS, OS and rs2010963 and 
rs699947 [9].
Sunitinib and pazopanib showed no statistical 
differences in their efficacy in our analysis, as reported 
in clinical trials. Nevertheless, a difference was found 
according to the biological genotype of tumoural cells. 
Patients with a favourable polymorphism had a good 
PFS either with sunitinib or pazopanib, but notably, the 
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favourable setting was the opposite for the two drugs. 
Our data seem to suggest that biology could have a role in 
the choice of first line treatment for mRCC patients. Our 
findings are preliminary and on a retrospective cohort of 
patients, they need to be validated in prospective studies 
and larger populations to be confirmed and enter the 
everyday clinical practice.
MATERIALS AND METHODS
Patients receiving first-line treatment for 
histologically proven advanced renal cell carcinoma with 
either sunitinib (78 patients) or pazopanib (19 patients), 
treated between 2010 to 2014, were eligible for analysis 
at our Institution.
Ethical Committee of our Institution approved the 
study design.
Follow-up consisted of physical examination, 
a complete blood count, chest radiography and US of 
the abdomen or CT/MRI scanning every 8 weeks or as 
clinically indicated.
VEGF and VEGFR genotyping was performed on 
formalin-fixed paraffin-embedded tissue block (about 30 
mg) of renal cell carcinoma samples in nephrectomy or 
core biopsies, taken from the neoplasm periphery.
Paraffin wax was removed with xylene and the 
samples were washed twice with 100% ethanol. DNA 
was isolated from the deparaffinised tissue using the 
RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE 
Tissues (Applied Biosystems, Foster City, CA, USA), 
according to the manufacturer’s instructions. DNA 
from each sample was then eluted in 120 μl of eluting 
solution.
Single nucleotide polymorphisms (SNPs) within 
each gene were selected using the Pupasuite software 
(http://pupasuite.bioinfo.cipf.es/index.jsf - version 
2.0.0, bioinfo 2008), the CIPF (Centro de Investigacion 
Principe Felipe) Single Nucleotide Polymorphism 
database (dbSNP) generated by the National Centre for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/
SNP) and by review of the medical literature, using the 
following criteria:
 1) the polymorphism had some degree of likelihood 
to alter the structure or the expression of the gene 
in a biologically relevant manner (i.e. affecting ese 
sequences, 3’ UTR or promoter region);
 2) the minor allele frequency was above 10% (with 
the only exception of rs2305948, rs6877011 and 
rs307822);
 3) the genetic polymorphism was established and well-
documented.
Further considerations drove the selection of SNPs 
for our study. A correlation between the presence of a 
specific allele on a polymorphic site and the expression 
of the respective protein has been previously documented 
for VEGF [28, 29]. SNPs in regulatory sequences, such 
as introns and 5’ and 3’ UTRs, have been shown to 
affect mRNA stability, processing efficiency, isoform 
expression and localization. Moreover, regulatory motif 
sequences within the 3’ UTR of mRNAs have been 
shown to affect the stability of the messenger and/or its 
translational efficiency. Thus, it can be argued that SNPs 
in these sequences may influence VEGF and VEGF-R 
gene expression. Also on these bases, we selected the 
SNPs known to affect VEGF and VEGF-R expression 
and those located in regulatory sequences, for which a 
putative role in protein regulation can be assumed.
Globally we assumed that selected SNPs had 
impact on protein expression and therefore on biological 
function.
Selected SNPs were as follows: six polymorphisms 
in the VEGFA gene (rs10434, G>A; rs2010963, G>C; 
Table 3: Polymorphisms results in univariate and multivariate analisys
Polymorphism Genotype
N. of Patients PFS (months)
OS
SUN PAZ SUN PAZ
VEGF A
rs833061 CC+CT 52 (66%) 13 (68%) 11,3 3,8
TT 26 (34%) 6 (32%) 4 9,3
p<0,0001 NR
rs2010963 GG+CG 59 (76%) 15 (79%) 7,7 4,48
CC 19 (24%) 4 (21%) 1,9 13,18
p<0,0001 NR
rs699947 AA+AC 52 (66%) 13 (68%) 9,5 3,7
CC 26 (34%) 6 (32%) 3,44 9,1
p<0,0001 NR
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rs25648, C>T; rs3025039, C>T; rs699947, A>C; rs833061, 
C>T), two in VEGFC (rs4604006, T>C; rs7664413, C>T), 
two in VEGF-R1 (FLT1) (rs664393, G>A; rs7993418, 
A>G), four in VEGF-R2 (KDR) (rs1870377, A>T; 
rs2071559, A>G; rs2305948, G>A; rs7667298, A>G) and 
three in VEGF-R3 (FLT4) (rs307805, A>G; rs6877011, 
C>G; rs307822, G>A). Chromosomal locations, positions 
and biological effects of investigated VEGF and VEGFR 
SNPs have been summarised in Table 1.
SNP genotyping was performed by TaqMan 
technology, using SNP genotyping products (Applied 
Biosystems, Foster City, CA). Polymerase chain reaction 
(PCR) was performed and genotypes were analysed on the 
7300 Real-Time PCR System (Applied Biosystems, Foster 
City, CA) using an ABI Prism 7300 Sequence Detection 
System software (version 1.3.1, Applied Biosystems, 
Foster City, CA). Each reaction contained 0.2 μl of total 
genomic DNA. Laboratory personnel blinded to patient 
status performed Genotyping, and a random 10% of the 
samples were repeated to validate genotyping procedures.
All SNPs genotyped had to present an overall call rate 
of ≥ 90% to be included in our analysis, all samples resulted 
significant during the analysis and didn’t need test repetition.
Primary aim of our study was PFS, OS was 
considered as secondary end-point.
In order to obtain a significant difference in the 
proportion of patients free of progression at 6 months 
according to genotyping and assuming a 6 months 
progression free survival (PFS) of 55% and ≥ 80% as a 
target, at least 85 patients were necessary with α=0.05 and 
β=0.05.
Statistical analysis was performed with the MedCalc 
software version 10.4.8 for Windows.
The association between categorical variables was 
estimated by Chi-square test.
Survival distribution was estimated by the Kaplan–
Meier method (Kaplan and Meier, 1958).
A significant level of 0.05 was chosen to assess the 
statistical significance.
For statistical analysis, overall survival (OS) and 
progression free survival (PFS) were defined as the interval 
between the date of beginning of first-line treatment to 
death or last follow-up visit, and to clinical progression or 
death or last follow-up visit if not progressed.
All polymorphisms were examined for deviation 
from Hardy-Weinberg equilibrium using the Powermarker 
v. 3.25 package (www.statgen.ncsu.edu/powermarker).
Linkage Disequilibrium (LD) analysis was also 
performed using the Powermarker v. 3.25 package (www 
.statgen.ncsu.edu/powermarker). LD was estimated using 
r2, with r2=1 indicating complete LD and r2=0 indicating 
absent LD.
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